PXVX0200 + placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cholera
Conditions
Cholera
Trial Timeline
Sep 1, 2013 → Nov 1, 2014
NCT ID
NCT01895855About PXVX0200 + placebo
PXVX0200 + placebo is a phase 3 stage product being developed by Bavarian Nordic for Cholera. The current trial status is completed. This product is registered under clinical trial identifier NCT01895855. Target conditions include Cholera.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02100631 | Phase 3 | Completed |
| NCT01895855 | Phase 3 | Completed |
| NCT01585181 | Phase 1 | Completed |
Competing Products
9 competing products in Cholera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Azithromycin | Pfizer | Phase 3 | 76 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Phase 3 | 76 |
| Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell + Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell | Sanofi | Approved | 84 |
| Ciprofloxacin | Bayer | Phase 3 | 74 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 3 | 74 |
| VAXCHORA (Cholera Vaccine, Live, Oral) | Bavarian Nordic | Approved | 82 |
| PXVX0200 Lot A + PXVX0200 Lot B + PXVX0200 Lot C + Placebo | Bavarian Nordic | Phase 3 | 74 |
| PXVX0200 + Placebo | Bavarian Nordic | Phase 1 | 30 |
| PXVX0200 10E8 + PXVX0200 10E9 + Placebo + Shanchol | Emergent BioSolutions | Phase 2 | 44 |